Ratings by Chardan
| Date | Analyst | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | Keay Nakae | Rocket Pharmaceuticals | RCKT | New Coverage | Buy (N/A) |
11.00 (N/A) |
3.72 (3.73) |
0.27% | Details |
| 8/28/2026 | James McIlree | Hyperliquid Strategies, Inc. | PURR | Maintain | Buy (N/A) |
17.00 (N/A) |
|
Details | |
 |
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
| 987 more... | |||||||||
